title: NBS1 Glu185Gln polymorphism and susceptibility to urinary system cancer: a meta-analysis.
abstract: A number of studies have investigated the association between the NBS1 Glu185Gln (rs1805794, 8360 G>C) polymorphism and risk for urinary system cancer including bladder cancer, prostate cancer, and renal cell cancer; however, the findings are conflicting. We conducted a meta-analysis focusing on eight published studies with 3,542 cases and 4,210 controls to derive a more precise evaluation of the relationship between the NBS1 Glu185Gln polymorphism and urinary system cancer susceptibility. Overall, the NBS1 Glu185Gln polymorphism was significantly related to increased risk for urinary system cancer (homozygous model: odds ratio (OR)=1.23, 95 % confidence interval (95% CI)= 1.05–1.44, p=0.011; heterozygous model: OR=1.14, 95% CI=1.04–1.26, p=0.008; dominant model: OR=1.16, 95% CI=1.05–1.27, p=0.002; and Gln vs. Glu: OR=1.12, 9% CI=1.04–1.20, p=0.002) and further stratification analysis indicated an increased risk for bladder cancer (heterozygous model: OR=1.13, 95% CI=1.02–1.26, p=0.022; dominant model: OR=1.14, 95% CI=1.03–1.26, p=0.014; and Gln vs. Glu: OR=1.09, 95%CI=1.01–1.18, p=0.023) and Caucasian populations (homozygous model: OR=1.33, 95% CI=1.11–1.59, p=0.002; heterozygous model: OR=1.16, 95% CI=1.04–1.30, p=0.009; dominant model: OR=1.19, 95% CI=1.07–1.32, p=0.001; and Gln vs. Glu: OR=1.15, 95% CI=1.06–1.25, p<0.001). Despite some limitations, this meta-analysis established some solid statistical evidence for the association between NBS1 Glu185Gln polymorphism and increased risk for urinary system cancer, especially for bladder cancer, but more well-designed prospective studies are needed to further verify our findings.
authors: State Key Laboratory of Oncology in South China, Blood Transfusion Department, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, China, zhangying1@sysucc.org.cn.
authors: Ying
authors: Y
authors: Zhang
authors: Yu-Shan
authors: YS
authors: Huang
authors: Wen-Qian
authors: WQ
authors: Lin
authors: Shao-Dan
authors: SD
authors: Zhang
authors: Qi-Wen
authors: QW
authors: Li
authors: Ye-Zhu
authors: YZ
authors: Hu
authors: Rong-Liang
authors: RL
authors: Zheng
authors: Tao
authors: T
authors: Tang
authors: Xi-Zhao
authors: XZ
authors: Li
authors: Xiao-Hui
authors: XH
authors: Zheng
mesh_terms: D016022:Case-Control Studies; D018797:Cell Cycle Proteins / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D009687:Nuclear Proteins / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000235:genetics*
chemical_list: D018797:Cell Cycle Proteins; C112156:NBN protein, human; D009687:Nuclear Proteins